Harsimran Singh
Adult Congenital Heart Disease · New York, NYNPI 1841224342
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $6,619 of the $9,728 with a category attached, or 68.0%. 15 manufacturers reported payments, led by Medtronic at 48.4% of the total. Reporting peaked in 2023 at $2,864 and has fallen 66.6% since, to $956 in 2025.
Across 93 payments — averaging $104.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$5K
- Abbott$2K
- Edwards Lifesciences$1K
- Spectrawave, Inc$378
- Philips North America LLC$268
- Shockwave Medical, Inc$200
- plus $780 from 9 others
What the payments were for
- Travel & lodging$3,10832%
- Food & beverage$6,61968%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 34 | $4,706 |
| Abbott | 35 | $1,969 |
| Edwards Lifesciences | 9 | $1,426 |
| Spectrawave, Inc | 3 | $378 |
| Philips North America LLC | 2 | $268 |
| Shockwave Medical, Inc | 1 | $200 |
| Boston Scientific | 1 | $174 |
| Abiomed | 1 | $154 |
| Endologix LLC | 1 | $150 |
| Heartflow, Inc. | 1 | $150 |
| Sumitomo Pharma America, Inc. | 1 | $69 |
| Johnson & Johnson | 1 | $31 |
| Amgen | 1 | $25 |
| Chiesi USA, Inc. | 1 | $15 |
| Lilly USA, LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- HARMONY$2,292
- Melody$1,067
- Edwards SAPIEN 3 Transcatheter Heart Valve$976
- MitraClip$404
- AMPLATZER$383
- HyperVue Imaging System$298
- Starlight Imaging Catheter$298
- (6574) Coronary Other$268
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$200
- Xience Sierra Coronary Stent System$189
- AVVIGO Guidance System$174
- Resolute$163
- Impella$154
- ENDOCROSS Device$150
- Torus Stent Graft System$150
- FFRct$150
- SAPIEN 3 Ultra RESILIA$145
- AMPLATZER Occluders$137
- Abre$133
- AMPLATZER TALISMAN$126
How this compares
Too few adult congenital heart disease providers in New Yorkto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 51 | $55,939 |
| EntrestoSacubitril/Valsartan | 39 | $40,441 |
| FarxigaDapagliflozin Propanediol | 23 | $35,011 |
| JardianceEmpagliflozin | 22 | $24,848 |
| XareltoRivaroxaban | 24 | $21,756 |
| BrilintaTicagrelor | 18 | $18,517 |
| Repatha SureclickEvolocumab | 14 | $12,072 |
| OzempicSemaglutide | 11 | $10,445 |
| Atorvastatin Calcium | 176 | $2,206 |
| Metoprolol Succinate | 182 | $2,065 |
| Eplerenone | 21 | $1,411 |
| Amlodipine-ValsartanAmlodipine Besylate/Valsartan | 16 | $877 |
| Amlodipine Besylate | 114 | $873 |
| Valsartan | 44 | $858 |
| Rosuvastatin Calcium | 63 | $841 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $31 | $21,75624 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few adult congenital heart disease providers in New Yorkon file to place this against a meaningful peer group, so we don't.
Other adult congenital heart disease in New York
- Robert SommerNew York$82K
- Jonathan KochavNew York$1K
- Noa Zemer WassercugNew York$983
- Yamini KrishnamurthyNew York$871
- Su YuanNew York$602
- Kali HopkinsNew York$494
- Eihab GhantousNew York$358
- Adam SmallNew York$322
- Matthew LewisNew York$69
- Emily SlaterNew York$0
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.